Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease.

Ransome MI, Renoir T, Hannan AJ.

Neural Plast. 2012;2012:874387. doi: 10.1155/2012/874387. Epub 2012 Jun 27. Review.

2.

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

Nithianantharajah J, Hannan AJ.

Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Epub 2012 May 24. Review.

PMID:
22633949
3.

Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies?

Gil-Mohapel J, Simpson JM, Ghilan M, Christie BR.

Brain Res. 2011 Aug 11;1406:84-105. doi: 10.1016/j.brainres.2011.06.040. Epub 2011 Jun 23. Review.

PMID:
21742312
4.

Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.

Giralt A, Saavedra A, Alberch J, Pérez-Navarro E.

J Huntingtons Dis. 2012;1(2):155-73. doi: 10.3233/JHD-120023. Review.

PMID:
25063329
5.

Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington's disease.

Mo C, Hannan AJ, Renoir T.

Neurosci Biobehav Rev. 2015 May;52:178-92. doi: 10.1016/j.neubiorev.2015.03.003. Epub 2015 Mar 10. Review.

PMID:
25770041
6.

Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.

van Dellen A, Grote HE, Hannan AJ.

Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1007-19. Review.

PMID:
16445565
8.

Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM.

Int J Biol Sci. 2014 Sep 10;10(9):1024-38. doi: 10.7150/ijbs.9898. eCollection 2014. Review.

9.

Neurodegenerative processes in Huntington's disease.

Bano D, Zanetti F, Mende Y, Nicotera P.

Cell Death Dis. 2011 Nov 10;2:e228. doi: 10.1038/cddis.2011.112. Review.

10.

Huntington's disease: pathogenesis to animal models.

Kumar P, Kalonia H, Kumar A.

Pharmacol Rep. 2010 Jan-Feb;62(1):1-14. Review.

11.

The use of transgenic and knock-in mice to study Huntington's disease.

Hickey MA, Chesselet MF.

Cytogenet Genome Res. 2003;100(1-4):276-86. Review.

PMID:
14526189
12.
13.

The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation.

Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC.

Mov Disord. 2014 Apr 15;29(5):673-83. doi: 10.1002/mds.25864. Review.

PMID:
24757115
14.

Role of cerebral cortex in the neuropathology of Huntington's disease.

Estrada-Sánchez AM, Rebec GV.

Front Neural Circuits. 2013 Feb 18;7:19. doi: 10.3389/fncir.2013.00019. eCollection 2013. Review.

15.

Transgenic mouse models of Parkinson's disease and Huntington's disease.

Skaper SD, Giusti P.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):455-70. Review.

PMID:
20522011
16.
17.

The psychopathology of Huntington's disease.

Folstein SE.

Res Publ Assoc Res Nerv Ment Dis. 1991;69:181-91. Review.

PMID:
1825887
18.

Selective neuronal degeneration in Huntington's disease.

Cowan CM, Raymond LA.

Curr Top Dev Biol. 2006;75:25-71. Review.

PMID:
16984809
19.

The early cellular pathology of Huntington's disease.

Li XJ.

Mol Neurobiol. 1999 Oct-Dec;20(2-3):111-24. Review.

PMID:
10966117
20.

Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.

Gil-Mohapel JM.

CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x. Review.

PMID:
21501423
Items per page

Supplemental Content

Write to the Help Desk